Pfizer Inc.
Pfizer Research Technology Center (RTC)
620 Memorial Drive
Cambridge
Massachusetts
02139
United States
Tel: 617-551-3000
Fax: 617-551-3111
Website: http://www.pfizer.com/
About Pfizer Inc.
The Pfizer Research Technology Center (RTC) in Cambridge, MA houses cutting edge research groups focused on RNAi therapeutics, Systems Biology and Biological Profiling, Regenerative Medicine and Computational Sciences.
Headquartered at the RTC, and comprising research groups in Cambridge and Düsseldorf, the goal of Pfizer RNAi Therapeutics is clear - delivering RNAi therapies to meet our patient needs and in doing so helping Pfizer become a top tier biotherapeutics company.
Pfizer Regenerative Medicine is collaborating with local experts to develop Stem Cell Therapies to treat diseases.
The Systems Biology, Biological Profiling and Computational Sciences groups are using their niche skills and expertise to focus on increasing the effectiveness of the research process through better target selection, reduced attrition and the ability to manipulate and manage data to support the research process.
Without the constraints of a therapeutic area portfolio, RTC colleagues are free to apply cutting-edge techniques and technologies with broad utility across different therapeutic areas.
The RTC is located in one of the richest scientific environments in the world, surrounded by more than 300 biotechnology companies and thousands of scientific innovators in world-leading research hospitals and academic institutions. A key element in the success of the RTC is the growing and dynamic portfolio of partnerships with these innovators, focused on addressing the strategic needs of the site and of Pfizer's research division.
The RTC aims to balance the strength of Pfizer R&D with the nimble feel of a small biotech, and creates an exciting and team-based scientific environment for 150 colleagues, with a wide range of scientific skills and experience. The working environment emphasizes collaboration and cooperation with most scientific questions solved through the work of a cross-disciplinary team. The unique working environment - truly a small biotech with the backing of the largest research budget in the industry - supports the unique science of the site.
For more information, please visit www.pfizercambridge.com
113 articles about Pfizer Inc.
-
Pfizer and BioNTech Report New Data on Omicron BA.4/BA.5-Adapted Bivalent Booster Demonstrating Improved Immune Response Against Emerging Omicron Sublineages
11/18/2022
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced results from an analysis examining the immune response induced by their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine [Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5)] against newer Omicron sublineages, including BA.4.6, BA.2.75.2, BQ.1.1 and XBB.1.
-
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster for Children 5 Through 11 Years of Age in European Union
11/10/2022
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced a booster dose of their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine (COMIRNATY ® Original/Omicron BA.4/BA.5 5/5-µg) has been recommended for marketing authorization by the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) for children 5 through 11 years of age.
-
Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster in Children 5 Through 11 Years of Age
10/12/2022
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the U.S. Food and Drug Administration (FDA) granted Emergency Use Authorization (EUA) for a 10-µg booster dose of their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine in children 5 through 11 years of age.
-
Pfizer Completes Acquisition of Global Blood Therapeutics
10/5/2022
Pfizer Inc. (NYSE: PFE) announced today the completion of its acquisition of Global Blood Therapeutics, Inc.
-
Pfizer Declares Fourth-Quarter 2022 Dividend
9/22/2022
Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.40 fourth-quarter 2022 dividend on the company’s common stock, payable December 5, 2022, to holders of the Common Stock of record at the close of business on November 4, 2022.
-
Pfizer and BioNTech Receive Positive CHMP Opinion for Conversion of COMIRNATY® Conditional Marketing Authorization to Full Marketing Authorization in the European Union
9/16/2022
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended converting the conditional Marketing Authorization (cMA) for COMIRNATY® [COVID-19 Vaccine (nucleoside modified)] to standard (also referred to as “full”) Marketing Authorization (MA) for all authorized indications and formulations.
-
Pfizer Invites Public to View and Listen to Webcast of Analyst and Investor Call to Review Oral GLP-1 Data Presented at European Association for the Study of Diabetes (EASD) 2022
9/14/2022
Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 4:30 p.m. EDT on Wednesday, September 21, 2022.
-
Akero Therapeutics Announces Two Financing Transactions with Pfizer Inc. and Hercules Capital, Inc. Providing Access to Up To $125 Million
6/16/2022
Akero Therapeutics Announces Two Financing Transactions with Pfizer Inc. and Hercules Capital, Inc. Providing Access to Up To $125 Million.
-
Pfizer, MorphoSys and Incyte Enter into Clinical Trial Collaboration for Monjuvi® (tafasitamab-cxix) in Combination with TTI-622, a Fusion Protein Directed Against CD47
6/13/2022
Pfizer, MorphoSys and Incyte Enter into Clinical Trial Collaboration for Monjuvi ® (tafasitamab-cxix) in Combination with TTI-622, a Fusion Protein Directed Against CD47.
-
Pfizer Provides Update on Ownership Interest in Haleon
6/1/2022
Haleon to Become a Publicly Listed Standalone Company in July Following a Demerger by GSK.
-
Pfizer Presents ELEVATE Pivotal Findings Demonstrating Etrasimod’s Potentially Best-in-Class Profile in Ulcerative Colitis
5/24/2022
Pfizer Inc. announced detailed results from two pivotal studies that make up the ELEVATE UC Phase 3 registrational program evaluating etrasimod, a once-daily, oral, selective sphingosine 1-phosphate receptor modulator for the treatment of moderately-to-severely active ulcerative colitis.
-
Everest Medicines' Licensing Partner Pfizer Presents ELEVATE Pivotal Findings Demonstrating Etrasimod's Potentially Best-in-Class Profile in Ulcerative Colitis
5/24/2022
Everest Medicines (HKEX 1952.HK) announced today that its licensing partner, Pfizer Inc. (NYSE: PFE) presented at Digestive Disease Week (DDW) 2022 detailed results from two pivotal studies that make up the ELEVATE UC Phase 3 registrational program evaluating etrasimod.
-
Andera Partners to sell its Life Sciences’ portfolio company ReViral to Pfizer
4/7/2022
Andera Partners announced today that Pfizer Inc. has entered into a definitive agreement to acquire Andera Life Sciences’ portfolio company ReViral Ltd.
-
Alnylam Pharmaceuticals Files Patent Infringement Suits against Pfizer and Moderna
3/17/2022
Alnylam Pharmaceuticals, Inc. announced today that it has separately filed suit in United States District Court for the District of Delaware against Pfizer, Inc. and Moderna, Inc., seeking damages for infringement of U.S. Patent No. 11,246,933 (the “’933 Patent”) in the parties’ manufacture and sale of their messenger RNA (mRNA) COVID-19 vaccines.
-
Pfizer Initiates Phase 2/3 Study of Novel COVID-19 Oral Treatment in Pediatric Participants
3/9/2022
Pfizer Inc. (NYSE: PFE) announced today that it has initiated a Phase 2/3 study, EPIC-PEDS (Evaluation of Protease Inhibition for COVID-19 in Pediatric Patients), to evaluate the safety, pharmacokinetics, and efficacy of Pfizer’s PAXLOVID.
-
Pfizer Granted FDA Breakthrough Therapy Designation for Respiratory Syncytial Virus (RSV) Vaccine Candidate for the Prevention of RSV in Infants from Birth up to Six Months of Age by Active Immunization of Pregnant Women
3/2/2022
Pfizer Inc. (NYSE:PFE) today announced that its respiratory syncytial virus (RSV) vaccine candidate, PF-06482077 or RSVpreF, received Breakthrough Therapy Designation from the US Food and Drug Administration (FDA).
-
Phase 3 CLOVER Trial for Pfizer’s Investigational Clostridioides Difficile Vaccine Indicates Strong Potential Effect in Reducing Duration and Severity of Disease Based on Secondary Endpoints
3/1/2022
Phase 3 CLOVER Trial for Pfizer’s Investigational Clostridioides Difficile Vaccine Indicates Strong Potential Effect in Reducing Duration and Severity of Disease Based on Secondary Endpoints.
-
Biohaven and Pfizer Receive Positive CHMP Opinion for Migraine Treatment
2/25/2022
Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) and Pfizer Inc. (NYSE: PFE) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion for rimegepant.
-
Biohaven and Pfizer Announce Positive Topline Results of Pivotal Trial of Rimegepant for the Acute Treatment of Migraine in China and South Korea
2/14/2022
Biohaven Pharmaceutical Holding Company Ltd. and Pfizer Inc. (NYSE: PFE), today announced positive top-line results from an Asia-Pacific, Phase 3 clinical trial of rimegepant in 1,431 adults for the acute treatment of migraine.
-
Pfizer Reports Fourth-Quarter and Full-Year 2021 Results
2/8/2022
Pfizer Inc. (NYSE: PFE) reported strong financial results for fourth-quarter and full-year 2021 and provided 2022 total company financial guidance(4).